In melanoma patients, the levels of circulating exosomal PD-L1 are positively correlated with the levels of IFN-γ, and exosomal PD-L1 is also a marker of immune activation after the initiation of treatment with PD-1-blocking antibodies, (53, 54). Here, CD274 is linked to melanoma.